Rachel Swansburg 10/18/25 Rachel Swansburg 10/18/25 GUARDIAN-101: A first in human, tumor agnostic phase 1 study evaluating safety and preliminary antitumor activity of CLSP-1025. Read More Julie DeSander 6/18/25 Julie DeSander 6/18/25 Researchers Showcase How AACR Project GENIE is Powering New Insights into Cancer Care Read More Rachel Swansburg 4/28/25 Rachel Swansburg 4/28/25 Clasp Therapeutics Doses First Patient in Phase 1 Clinical Trial with a First-in-Class T-Cell Engager Designed to Target Cancer Cells with Absolute Specificity Read More Rachel Swansburg 4/28/25 Rachel Swansburg 4/28/25 Clasp Therapeutics Presents Nonclinical Data Supporting GUARDIAN-101 Phase 1 Clinical Study of CLSP-1025 at the 2025 AACR Annual Meeting Read More Rachel Swansburg 4/28/25 Rachel Swansburg 4/28/25 CLSP-1025, a first-in-class precision T-cell engager for the treatment of p53 mutant cancers Read More Rachel Swansburg 11/7/24 Rachel Swansburg 11/7/24 CLSP-1025, a novel bispecific T-cell engager targeting the p53R175H mutant peptide presented by HLA-A*02:01 Read More Jamison Wright 11/7/24 Jamison Wright 11/7/24 Clasp Therapeutics Presents Comprehensive Preclinical Data Validating First-in-Class Precision T Cell Engager Against p53 Mutant Solid Tumors at SITC Annual Meeting Read More Jamison Wright 10/4/24 Jamison Wright 10/4/24 Clasp Therapeutics to Present Preclinical Data Evaluating Novel T Cell Engager Targeting p53 Mutant Solid Tumors Read More Jamison Wright 8/20/24 Jamison Wright 8/20/24 Clasp Therapeutics Receives DC Inno Fire Award Read More Jamison Wright 3/20/24 Jamison Wright 3/20/24 Clasp Therapeutics launches with $150 million in hand Read More Jamison Wright 3/20/24 Jamison Wright 3/20/24 Clasp Therapeutics emerges with $150M based on work from Bert Vogelstein, Drew Pardoll Read More Jamison Wright 3/20/24 Jamison Wright 3/20/24 Clasp Therapeutics Launches with $150 Million to Pioneer Precision Immuno-Oncology Using Next-Generation T Cell Engagers with Unparalleled Specificity Read More
Rachel Swansburg 10/18/25 Rachel Swansburg 10/18/25 GUARDIAN-101: A first in human, tumor agnostic phase 1 study evaluating safety and preliminary antitumor activity of CLSP-1025. Read More
Julie DeSander 6/18/25 Julie DeSander 6/18/25 Researchers Showcase How AACR Project GENIE is Powering New Insights into Cancer Care Read More
Rachel Swansburg 4/28/25 Rachel Swansburg 4/28/25 Clasp Therapeutics Doses First Patient in Phase 1 Clinical Trial with a First-in-Class T-Cell Engager Designed to Target Cancer Cells with Absolute Specificity Read More
Rachel Swansburg 4/28/25 Rachel Swansburg 4/28/25 Clasp Therapeutics Presents Nonclinical Data Supporting GUARDIAN-101 Phase 1 Clinical Study of CLSP-1025 at the 2025 AACR Annual Meeting Read More
Rachel Swansburg 4/28/25 Rachel Swansburg 4/28/25 CLSP-1025, a first-in-class precision T-cell engager for the treatment of p53 mutant cancers Read More
Rachel Swansburg 11/7/24 Rachel Swansburg 11/7/24 CLSP-1025, a novel bispecific T-cell engager targeting the p53R175H mutant peptide presented by HLA-A*02:01 Read More
Jamison Wright 11/7/24 Jamison Wright 11/7/24 Clasp Therapeutics Presents Comprehensive Preclinical Data Validating First-in-Class Precision T Cell Engager Against p53 Mutant Solid Tumors at SITC Annual Meeting Read More
Jamison Wright 10/4/24 Jamison Wright 10/4/24 Clasp Therapeutics to Present Preclinical Data Evaluating Novel T Cell Engager Targeting p53 Mutant Solid Tumors Read More
Jamison Wright 8/20/24 Jamison Wright 8/20/24 Clasp Therapeutics Receives DC Inno Fire Award Read More
Jamison Wright 3/20/24 Jamison Wright 3/20/24 Clasp Therapeutics launches with $150 million in hand Read More
Jamison Wright 3/20/24 Jamison Wright 3/20/24 Clasp Therapeutics emerges with $150M based on work from Bert Vogelstein, Drew Pardoll Read More
Jamison Wright 3/20/24 Jamison Wright 3/20/24 Clasp Therapeutics Launches with $150 Million to Pioneer Precision Immuno-Oncology Using Next-Generation T Cell Engagers with Unparalleled Specificity Read More
